Allakos Inc
Allakos Inc logo
ALLK

Allakos Inc (ALLK)

$8.253.9%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$7.91
Day's Range
$8.275
$2.54
52-Week Range
$86.95
1 month return39.36%
3 month return74.79%
1 year return89.64%
5 year return73.6%

Company Information

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis.
OrganizationAllakos Inc
Employees192
CEODr. Robert Alexander Ph.D.
IndustryHealth Technology

Analyst Recommendation

based on 12 analysts ratings

Buy
66%
Buy
16%
Hold
16%
Sell

Based on 12 Wall street analysts offering stock ratings for Allakos Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Downside of 17.21%

Current

$8.25

Target

$6.83

Recommendation Trend

Based on 12 analyst

Current1M Ago3M Ago
Buy
8
3
8
Hold
2
8
8
Sell
2
6
2
Consensus
BUY
HOLD
BUY

Highlights

Market Capitalization
676.5M
Book Value
$4.04
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-7.59
Wall Street Target Price
6.83

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
1.82
Enterprise Value
351.6M
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
-0.96

Technicals

Beta
0.4
50 Day MA
6.34
200 Day MA
4.78

Institutional Holdings

Logos Global Management LP

6.97%

RiverVest Venture Management LLC

5.74%

Vivo Capital, LLC

4.84%

Vanguard Group Inc

3.65%

Redmile Group, LLC

2.99%

NEA Management Company, LLC

2.54%

Discover more

Frequently Asked Questions

What is Allakos Inc share price today?

Can Indians buy Allakos Inc shares?

How can I buy Allakos Inc shares from India?

Can Fractional shares of Allakos Inc be purchased?

What are the documents required to start investing in Allakos Inc stocks?

What are today’s High and Low prices of Allakos Inc?

What are today’s traded volumes of Allakos Inc?

What is today’s market capitalisation of Allakos Inc?

What is the 52 Week High and Low Range of Allakos Inc?

How much percentage Allakos Inc is down from its 52 Week High?

How much percentage Allakos Inc is up from its 52 Week low?

What are the historical returns of Allakos Inc?

Who is the Chief Executive Officer (CEO) of Allakos Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*